This article available in Chinese version only

阿里健康及海底撈將染藍 若看好可留意里康購20685/海撈購26640

2021-03-01 10:31:29

恒指服務公司公布最新一份季檢,阿里健康(0241)及海底撈(6862)等納入恒生指數,成分股由52增加至55隻,所有變動將於3月15日起生效。報導指,市場預計被動基金將要追入阿里健康超過14億元,另海底撈則超過9億元。阿里健康及海底撈股價受刺激早段開盤分別升逾7%及8%。兩者股價皆於2月創新高,上周五阿里健康回試50天線,今早重上10天線28.1元之上,如看好可留意輕微價外認購證20685,行使價 30.88 元, 2021年7月到期 ,實際槓桿 4.1 倍 。

 

有大行於2月初列出2021年以來北水首20大最吸資股分,海底撈排第12,有約5.9億美元。海底撈2月中曾見上市高位85.8元,惟股價於大市2月下旬回落時出現較明顯調整,上周五於100天線約61元之上暫喘定,投資者若認為染藍的消息或有助股價及波幅向好,可留意貼價認購證26640,行使價 69 元, 2021年10月到期 ,實際槓桿 3.2 倍。

 

其他滙豐輪證焦點:

 

里康認購證20685,行使價 30.88 元, 2021年7月到期 ,實際槓桿 4.1 倍。

平醫認購證27671,行使價 136.98 元, 2021年7月到期 ,實際槓桿 5.2 倍。

平醫牛證54259,行使價 97.38 元, 收回價 101.38 元, 2021年11月到期 ,實際槓桿 5.5 倍。

 

海撈認購證26640,行使價 69 元, 2021年10月到期 ,實際槓桿 3.2 倍。

九毛認購證26395,行使價 25.88 元, 2021年6月到期 ,實際槓桿 2.7 倍。

Intrady newsletters
Back to Intrady newsletters
本結構性產品並無抵押品,如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。

本文由香港上海匯豐銀行有限公司(「本行」或「發行商」)發行(包括任何參考條款),僅供參考之用,並不構成邀約、游說、或建議出售或購買結構性產品。

結構性產品屬複雜產品,投資者務須就此審慎行事,除非投資者完全了解及願意承擔所涉風險,否則切勿投資此產品。結構性產品價格可急升可急跌,投資者或會損失所有或大部分投資。過往表現並不反映將來表現。投資前應了解結構性產品之性質及風險,並詳閱有關上市文件,獨立決定是否適合自己,若需要應諮詢專業建議。本行及其委任之流通量提供者可能是結構性產品的唯一市場參與者,而結構性產品的二級市場可能有限。謹請注意,牛熊證設有強制收回機制,因此有可能提早終止,在此情況下(i)N類牛熊證投資者會損失於牛熊證的全部投資;而(ii)R類牛熊證之剩餘價值則可能為零。界內證在市場是全新的結構性產品,現時在香港交易所並無類似上市產品可作比較。界內證具備有別於標準的特徵,其條款及定價或較其他標準權證複雜,其最大潛在回報為固定及設有上限。界內證價格變動可能與其掛鈎資產的價格變動不成比例或呈相反方向。

作者為金管局及證監會持牌人士,並無就結構性產品或相關資產持有任何直接或間接權益。
Sign up to our newsletter

Stay abreast of the trends with the latest investment insight and market updates.

Latest article

(Available in Chinese only)
Back to Intrady newsletters

Important Risk Warning

The structured products are not collateralized. If the issuer is insolvent or defaults, investors may not recover part or all of the amount due.

Structured products are complex products. Investors should exercise caution in relation to them. The price of the structured products may fall in value as rapidly as it may rise and investors may sustain a total or substantial loss of their investment. Prospective investors should ensure that they understand the nature and risks and seek professional advice where applicable. Please also note that CBBCs have a mandatory call feature and may therefore be subject to early termination, upon which (i) investors in category N CBBCs will lose all of their investments in the CBBCs; and (ii) the residual value of category R CBBCs may be zero. Inline warrants have been newly introduced to the market and there are no similar products currently listed on the Stock Exchange of Hong Kong Limited for comparison. Inline warrants carry exotic features, and their terms and pricing may be more complicated than standard derivative warrants. Maximum potential payoff is fixed and capped. Price movement of the inline warrants may be disproportionate or opposite to the price movement of the underlying asset. Trading structured products with United States (US) underlying index may be exposed to additional risks, including (a) risks relating to difference in trading days and hours, (b) less public information about the index and such information may not be available in Chinese, (c) political and economic risks relating to the index regions (such as the US), (d) exchange rate risks, (e) possible delay in settlement, and (f) publication of index level when component shares are not trading. Click here for "Terms of Use".

Disclaimer

By viewing this website or using any information or functions of this website, you are deemed to acknowledge that you agree to the Privacy and Security, Terms of Use and Hyperlink Policy. Click here for "Disclaimer".

All data/charts are for reference purposes only.